Skip to Content

Ceprotin Approval History

FDA Approved: Yes (First approved March 30, 2007)
Brand name: Ceprotin
Generic name: protein C
Dosage form: Injection
Company: Baxter Healthcare Corporation
Treatment for: Protein C Deficiency

Ceprotin is a plasma-derived Protein C concentrate for use as replacement therapy in patients with life-threatening blood-clotting complications related to severe congenital Protein C deficiency.

Development History and FDA Approval Process for Ceprotin

DateArticle
Mar 30, 2007Approval Baxter Announces FDA Approval Of Ceprotin For Severe Congential Protein C Deficiency

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide